BG
ENTA icon

BlackRock Group’s Enanta Pharmaceuticals ENTA Stock Holding History

BlackRock Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$963K Buy
28,737
+11,723
+69% +$336K ﹤0.01% 2150
2016
Q3 		$453K Buy
17,014
+4,976
+41% +$116K ﹤0.01% 2343
2016
Q2 		$265K Buy
12,038
+882
+8% +$23.1K ﹤0.01% 2472
2016
Q1 		$327K Buy
11,156
+819
+8% +$22.8K ﹤0.01% 2400
2015
Q4 		$341K Sell
10,337
-2,191
-17% -$71.4K ﹤0.01% 2350
2015
Q3 		$453K Buy
12,528
+848
+7% +$36.4K ﹤0.01% 2244
2015
Q2 		$525K Buy
11,680
+1,783
+18% +$69.4K ﹤0.01% 2249
2015
Q1 		$303K Buy
9,897
+1,767
+22% +$68.8K ﹤0.01% 2353
2014
Q4 		$413K Sell
8,130
-5,922
-42% -$265K ﹤0.01% 2300
2014
Q3 		$556K Buy
14,052
+9,011
+179% +$359K ﹤0.01% 2130
2014
Q2 		$217K Buy
5,041
+3,767
+296% +$144K ﹤0.01% 2438
2014
Q1 		$51K Buy
+1,274
New +$46.3K ﹤0.01% 2641
2013
Q4 		– Sell
-1,382
Closed -$32K – 2699
2013
Q3 		$32K Buy
+1,382
New +$26.4K ﹤0.01% 2770

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's ENTA Position: Q4 2016 in Review

BlackRock Group increased its Enanta Pharmaceuticals (ENTA) stake by 69% in Q4 2016, buying an estimated $336K and bringing the position to 28,737 shares worth $963K. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

BlackRock Group first reported a position in ENTA in Q3 2013 and has held it in 13 quarters since. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

  • BlackRock Group held 28,737 shares of Enanta Pharmaceuticals worth $963K as of Q4 2016.
  • BlackRock Group bought 11,723 Enanta Pharmaceuticals shares in Q4 2016, an estimated $336K.
  • Enanta Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2150 holding.
  • BlackRock Group first reported a position in Enanta Pharmaceuticals in Q3 2013 and has held it in 13 quarters since.
  • 149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.